

The Lp(a) Horizon Study

For adults 18 to 80 years old who have cardiovascular disease and high lipoprotein(a) levels

Dear Sir/Madam,

As someone who has **cardiovascular disease and high lipoprotein(a) [Lp(a)] levels**, you may be interested in learning about a clinical study sponsored by Novartis called the Lp(a) Horizon Study.

A high Lp(a) level doesn't cause symptoms but it is a risk factor for causing a serious **cardiovascular event**, such as a heart attack or stroke. A high Lp(a) level is caused by your genes, so even if other risk factors such as cholesterol, blood pressure, and diabetes are under control, your cardiovascular risk is higher. There is currently no treatment for this condition.

What is the purpose of the Lp(a) Horizon study?

The purpose of the study is to examine the effectiveness of a new investigational medicine called **pelacarsen** in safely helping people with cardiovascular disease and high levels of Lp(a) lower their risk of a serious cardiovascular event.

What is the investigational medicine?

Participants will receive either the investigational drug pelacarsen or placebo, which contains no active drug. Both are given as an injection under the skin once every month. Participants have a 50/50 chance of getting pelacarsen or placebo.

What happens during the study?

The study lasts from 2.5 years up to about 4.25 years*. It is broken into 3 parts:

Screening

1 visit to make sure the study is right for you

Cardiovascular risk management

1 to 3 monthly visits to make sure your other risk factors are under control

Treatment

Monthly visits for 6 months, then one visit every 3 months for 1.5 years, then every 6 months for the final 2 years with some regular contact by phone

2.5 to 4.25 years*

*Depending on how long the study has already been in progress when you join.

Right now there are no available treatments to lower high Lp(a) levels. That's why it's so important for patients like you to participate! Participation is entirely voluntary.



To learn more about the Lp(a) Horizon Study, please contact:

Monash Cardiovascular Research Centre

Email: mcrc@monashhealth.org

Telephone: 9594 4543

You can also watch a video with more information at [URL PLACEHOLDER]

QR code